• Loading stock data...
Slide background

BOARD OF DIRECTORS

Eric-Leire-

Eric Leire

Dr. Eric Jean Marie Leire (born 1957) brings to Blake Insomnia Therapeutics a valued combination of medical professionalism with business acumen spanning over 30 years encompassing:

  • Biotech – held executive positions with Paringenix, APT Therapeutics, and Biostrategies Group;
  • Pharmaceutical – served in senior management at Pfizer, Boots Pharma, Schering Plough Pharmacia;
  • Private Equity – partner at Biofund Venture and Medwell Capital;
  • Non-Profit – HIV/AIDS Project Manager with Doctors of the World, establishing educational programs and coordinating with United Nations organization such as UNHCR, UNAIDS, UNICEF and UNDP; and
  • Academia – Research Associate at the Harvard University AIDS Institute.

Dr. Eric Leire earned his MD from Grenoble University Medical School in Grenoble, France, and also holds an MBA with a Finance specialization from Institute Superieure des Affaires in Paris, France and a MBA with a Health Care Management specialization from the Kellogg Graduate School of Management, Northwestern University in Chicago, IL.

Dr. Leire’s experience in the biotech industry, brings strong merit and expertise to Blake Insomnia’s future plans to engage drug regulatory agencies and conduct clinical trials. It is important to note that the Biotech industry possess the most stringent regulatory procedures that need to be fulfilled in order to achieve market approval. Given the strategic position of ZLX-1 compound and the large unmet clinical need for insomnia sufferers, Dr. Leire welcomes the opportunity to improve patient access to much needed treatment and will start working on the board as soon as the Company has obtained Director’s and Officer’s Insurance.

Dr. Leire is the CEO of DanDrit Biotech (OTCQB: DDRT) which is developing a dendritic cell-based immunotherapy for the treatment of advanced colorectal cancer (Phase III clinical trials). He also serves on the Board of Novicol International Holding Inc., a Canadian company with a microbicide commercially available in China.

Kyle-Sarwal

Kyle Sarwal

Kyle Sarwal is a proven entrepreneur and a director of SAJO consulting. He serves as a valuable member of the Board who possesses outstanding expertise in technology and business consulting. Mr. Sarwal is an expert of many industries and a serial entrepreneur with over 20 years of experience in acquiring and growing companies, managing technology and information systems, managing teams and businesses, advisory and strategic planning. Kyle has worked with clients from a wide variety of industries, some of which include manufacturing, education, transportation, government and municipalities, hospitality, retail and most importantly healthcare.

A motivated businessman Kyle Sarwal started his first businesses while in high school. His passion and outstanding expertise in technology allowed Kyle to found KS Systems in 1999. This new venture supported his continued involvement in developing value innovations in the technology space for small size businesses and private clients. Building up on his success, Kyle laid out the foundation for LinkPoint IT Solutions Ltd. – a managed service provider servicing businesses across the Greater Vancouver Area. Soon enough, the company transitioned to consulting and development initiatives across many industries, developing software products required to meet the growing needs of integration across platforms, and providing research and development of unique opportunities based on value innovation principles. Mr. Sarwal wants to grow his businesses even further and establish their presence worldwide.

Today, he leads a diverse group of professionals in his quest to delivering innovation and value to an impressive list of clients. His vision, ambition and dedication in serving clients is the key to success of his ventures.

AJIT JOHAL

Ajit Johal

Ajit Johal is a passionate pharmaceutical expert who has been widely recognized for his educational efforts and involvement in the community. Mr. Johal has been providing valuable advice to the Blake Insomnia Therapeutics team in their research and development efforts.

In 2012 Ajit has graduated from the Leslie Dan Faculty of Pharmacy program at the University of Toronto, and has been practicing at Wilson Pharmacy (Port Coquitlam, BC) since graduation. He started of as a community pharmacist and was the lead clinical pharmacist for many outreach programs, such as Coat Mental Health Medication Program. Ajit was also involved in the Integrated Medication Management Program, non-profit “S.U.C.C.E.S.S.” and the Mental Health Family education series.  Currently, he is the clinical services coordinator.

Since 2013, Ajit has worked with the UBC Pharmacy SPEP program as a preceptor for pharmacy students. Later on, in 2015, Mr. Johal has become the course coordinator for the Pharmacy 450b at the University of British Columbia. This was the first elective course in Travel Medicine available to Pharmaceutical Students in Canada.

Ajit is always looking to further his knowledge, and has received certifications in the clinical areas of travel medicine in 2014 and diabetes in 2015. To this day he works with many diabetic patients in the community, as well as provides pre-travel consultation services. Furthermore, he was one of the main presenters at the BCPHA and CPHA conferences in 2016, sharing his knowledge about COPD, Diabetes, and Travel Medicine.

Awards

  • 2013 – “Shining Example Award” by Coast Mental Health for his role in staff education.
  • 2014 – “Practice Educator of the Year” award from the UBC for outstanding student mentorship.
  • 2016 – “New Practitioner Award” from the British Columbia Pharmacy Association for demonstrating excellence in the pharmacy profession.
Advisory Board

Morten Albrechtsen

Morten Albrechtsen is an experienced business leader with a strong medical, commercial and financial background. After holding executive positions at several large pharmaceutical companies, including Boehringer Ingelheim and Nycomed (later acquired by Takeda Pharmaceutical), he founded ENKAM Pharmaceuticals in 2001. Since then, he has divided his time between consultancy work and executive roles, primarily at companies 2–4 years prior to cash-generating transactions. In addition to his role at Blake, Morten serves as co-founder and CEO at radiotherapy specialists Nanovi, part-time CEO at a number of pharma-related startups and executive chairman at the clinical CRO NORMA. Known as an expert deal-maker, Morten has extensive experience with turnarounds, spinoffs, business development, licensing and corporate deals, including M&A and financing.